UNSPSC 51392219: Clonidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H9Cl2N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W76I6XXF06, chemically known as 2-imidazoline, 2-(2,6-dichloroanilino)-, monohydrochloride but more generally known as clonidine hydrochloride, which bears US NIH Compound Identifier 20179. European Medicines Agency schedules Clonidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01362MIG.

Most nations, for tariff and trade purposes, schedule clonidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, CLONIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clonidine hydrochloride bears US NLM identifiers UMLS ID C0546860 and NCI Concept Code C47979. SMILES: C1CC(C(C(C1)CL)NC2=NCCN2)CL.CL.

UNSPSC 51392219 Clonidine hydrochloride is a Commodity code for a specific pharmaceutical product, but recent state and local solicitations tagged under this code do not reflect actual procurement of clonidine itself. Instead, the opportunities posted under the code involve purchase of naloxone and drug deactivation systems (Seminole County, Florida) and a market-intelligence request for direct-to-manufacturer pharmacy benefit program capabilities (Texas Health and Human Services Commission). The mismatch between the code's nominal scope and the actual work being solicited suggests either tagging errors in the posting systems or that the code is being used as a proxy for broader pharmaceutical and drug-management procurement. State and local issuing bodies using this code include county health departments and state human services agencies focused on community health initiatives, substance-abuse intervention, and prescription-management efficiency.

Recent activity appears concentrated in Florida and Texas. Seminole County posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the bid response deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models and prescription fulfillment strategies outside traditional pharmacy benefit manager and wholesaler channels. No budget ranges, contract values, or set-aside designations appear in either opportunity.